Investigation of pilocarpine oxidative and hydrolytic metabolism in chimeric mice with humanized liver
Drug Metabolism and Pharmacokinetics · 2025
DOI: 10.1016/j.dmpk.2025.101484 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Metabolism and Pharmacokinetics, 2025. Verfasst von Shotaro Uehara und 4 weiteren Autor:innen. Beteiligte Einrichtung: Liver Engineering Laboratory, Department of Applied Research for Laboratory Animals, Central Institute for Experimental Medicine and Life Science, Ka…. Hauptthemen laut MEDLINE: Pilocarpine, Liver. Die Arbeit nennt 22 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Chimeric mice with humanized liver (humanized-liver mice) are an attractive alternative to conventional animals for predicting pharmacokinetics in humans. We aimed to investigate the role of CYP2A6 and PON1 on pilocarpine biotransformation in humanized-liver mice. Following a single oral dose of 10 mg/kg, higher plasma concentrations of pilocarpine and 3-hydroxypilocarpine were observed in humanized-liver mice than in non-humanized mice. The ratios of area under the curve (AUC) to total AUC for pilocarpine in humanized-liver mice were more similar to those observed in humans with extensive metabolizer phenotypes for CYP2A6 compared to those in non-humanized mice for both 3-hydroxypilocarpine and pilocarpic acid. Pilocarpine 3-hydroxylase activity in liver microsomes was higher in humanized-liver mice than in non-humanized mice, whereas the pilocarpine hydrolase activity in plasma was comparable between both groups. CYP2A6 levels and pilocarpine 3-hydroxylase activities in liver microsomes from humanized-liver mice were correlated (P = 0.04). Furthermore, both hepatic microsomal 3-hydroxylase and plasma hydrolase activities of pilocarpine in humanized-liver mice decreased in the presence of respective human CYP2A6 or PON1 inhibitors. The plasma metabolite profiles of pilocarpine in humanized-liver mice were similar to those in humans, highlighting the suitability of humanized-liver mice for investigating CYP2A6-and PON1-dependent drug biotransformation in humans.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Liver Engineering Laboratory, Department of Applied Research for Laboratory Animals, Central Institute for Experimental Medicine and Life Science, Kawasaki-ku, Kawasaki, Kanagawa, 210-0821, Japan. Electronic address: s-…
- Liver Engineering Laboratory, Department of Applied Research for Laboratory Animals, Central Institute for Experimental Medicine and Life Science, Kawasaki-ku, Kawasaki, Kanagawa, 210-0821, Japan.
- Laboratory of Drug Metabolism and Pharmacokinetics, Showa Pharmaceutical University, Machida, Tokyo, 194-8543, Japan.
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Uehara, S., Higuchi, Y., Yoneda, N., Yamazaki, H., & Suemizu, H. (2025). Investigation of pilocarpine oxidative and hydrolytic metabolism in chimeric mice with humanized liver. Drug Metabolism and Pharmacokinetics. https://doi.org/10.1016/j.dmpk.2025.101484
Vancouver
Uehara S, Higuchi Y, Yoneda N, Yamazaki H, Suemizu H. Investigation of pilocarpine oxidative and hydrolytic metabolism in chimeric mice with humanized liver. Drug Metabolism and Pharmacokinetics. 2025. doi:10.1016/j.dmpk.2025.101484
BibTeX
@article{Uehara2025,
author = {Uehara, Shotaro and Higuchi, Yuichiro and Yoneda, Nao and Yamazaki, Hiroshi and Suemizu, Hiroshi},
title = {Investigation of pilocarpine oxidative and hydrolytic metabolism in chimeric mice with humanized liver},
journal = {Drug Metabolism and Pharmacokinetics},
year = {2025},
doi = {10.1016/j.dmpk.2025.101484}
}
EUVIMED